India’s Zydus Has Expansion Plans In Japan After Nippon Acquisition
This article was originally published in PharmAsia News
Zydus Cadila, an Indian pharmaceutical company, plans to release its first new generic drug in 10 years and expand its portfolio of other generics in Japan. Zydus acquired the Japanese generics maker, Nippon Universal Pharmaceutical, last April. The new drug launched by Zydus is a generic of UCB Japan's Zyrtec (cetirizine hydrochloride) for treating allergies. The Nippon arm plans to acquire the sales rights for nine other generics drugs to add to its portfolio of six, and increase its sales representative staff from 11 to 25 by next October. (Click here for more - may require a subscription
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.